Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.
This Rituxan Hycela, Rituxan Mabthera (Rituximab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Rituxan Hycela and Rituxan MabThera (rituximab) are monoclonal antibody therapies that target CD20-positive B-cells. These treatments are used for conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan Hycela is a subcutaneous formulation, while Rituxan MabThera is administered intravenously.
The main formulations of Rituxan Hycela and Rituxan MabThera (rituximab) are available in 10 ml and 50 ml vials. The 10 ml vial of Rituxan Hycela is intended for patients who require a smaller dose of the medication, often suitable for those beginning treatment or needing lower dosages, allowing for personalized care. The medication is administered through subcutaneous, intravenous, and parenteral routes and is distributed through hospital pharmacies, online pharmacies, and other channels. It is used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions.

The key companies operating in the rituxan hycela, rituxan mabthera (rituximab) market is F. Hoffmann-La Roche AG (Genentech Inc.) North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2024. The regions covered in rituxan hycela and rituxan mabthera (rituximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rituxan hycela and rituxan mabthera (rituximab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Market growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of non-Hodgkin's lymphoma, the growing adoption of biologics, favorable reimbursement policies, and improving healthcare infrastructure. Growth during the market's forecast period can be attributed to the rising geriatric population, increasing patient awareness, growth in emerging markets, supportive government policies, and the growing demand for targeted therapies. Key trends during this period include a shift towards subcutaneous formulations, increased competition from biosimilars, strategic collaborations among market players, a focus on patient-centric treatment options, and geographic expansion into developing regions.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, leading to inflammation and potential damage. The rise in these conditions is linked to factors such as genetic predisposition, environmental factors, infections, and lifestyle changes that impact the immune system.

Rituximab helps manage autoimmune diseases by targeting and depleting specific immune cells (B-cells) that mistakenly attack healthy tissues. For example, in October 2023, a report from the National Health Service England highlighted the ongoing rise in the prevalence of diabetes. In England, the number of people with type 1 diabetes increased to 270,935 between 2021 and 2022. This rising incidence of autoimmune diseases is a key factor driving the market for Rituxan Hycela and Rituxan MabThera (rituximab).
The growing healthcare expenditure is another factor expected to propel the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Healthcare expenditure encompasses all spending on healthcare goods and services, including personal health care, preventive services, and public health activities, which aim to improve health outcomes. This expenditure is increasing due to factors such as an aging population, the rise of chronic diseases, advancements in medical technology, high drug prices, and increased demand for healthcare services.

Higher healthcare spending improves access to advanced treatments such as Rituxan Hycela and Rituxan MabThera, boosting demand for effective therapies in the treatment of oncology and autoimmune diseases. For instance, in May 2024, a report from the Office for National Statistics noted that healthcare expenditure in the UK rose by 5.6% from 2022 to 2023, compared to a slower growth rate of 0.9% in 2022. Long-term health and social care expenditure also saw an increase of 2.8% in real terms in 2022. The rise in healthcare spending is contributing to the growth of the Rituxan Hycela and Rituxan MabThera market.
A significant trend in the Rituxan Hycela and Rituxan MabThera (rituximab) market is the development of biosimilar anti-CD20 monoclonal antibodies, which offer cost-effective alternatives and improve patient access to treatment. Biosimilars are biologic drugs highly similar to reference products such as Rituxan, designed to target CD20 on B-cells and provide a more affordable treatment option. RIABNI is a biosimilar version of Rituxan, containing the same amino acid sequence and available in the same dosage form, strength, and administration route. The development of such biosimilars is expected to further drive the market for Rituxan Hycela and Rituxan MabThera.
Key Topics Covered:
1. Executive Summary
2. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Characteristics
3. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends and Strategies
5. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Growth Analysis and Strategic Analysis Framework
6.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Growth Rate Analysis
6.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Historic Market Size and Growth, 2019-2024, Value ($ Million)
6.5. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)
6.6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Total Addressable Market (TAM)
7. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Pricing Analysis & Forecasts
8. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Segmentation
8.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• 10ml
• 50ml

8.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Subcutaneous
• Intravenous
• Parenteral

8.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Hospital Pharmacy
• Online Pharmacy
• Others Distribution Channel

8.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Non-Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Rheumatoid Arthritis
• Other Applications

9. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Regional and Country Analysis
10.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109522688